Lista de obras - N J Curtin - Dominio Público Uruguay

1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.

artículo científico publicado en 2013

4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.

artículo científico publicado en 2003

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance

artículo científico publicado en 2010

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

article

A radioimmunoassay for deoxythymidine triphosphate

scientific article published on 01 December 1989

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms

artículo científico publicado en 2020

Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples.

artículo científico publicado en 2014

Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines

artículo científico publicado en 2000

Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

artículo científico publicado en 2000

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

artículo científico publicado en 2010

Changes in developmental-specific enzyme activities during experimental hepatocarcinogenesis in the rat in vivo [proceedings]

artículo científico publicado en 1980

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting

scientific article published on 17 July 2020

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor

artículo científico publicado en 2018

Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K

artículo científico publicado en 2012

Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer

artículo científico publicado en 2015

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival

artículo científico publicado en 2012

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

artículo científico publicado en 2017

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition ⬇️

artículo científico publicado en 2015

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

artículo científico publicado en 2011

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

artículo científico publicado en 2013

DNA damage checkpoint kinases in cancer

artículo científico publicado en 2020

DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767.

artículo científico publicado en 2002

DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype ⬇️

artículo científico publicado el 16 de noviembre de 2010

DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin

artículo científico publicado en 2013

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

artículo científico publicado en 2014

Defective homologous recombination in human cancers.

scientific article published on 28 June 2011

Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.

artículo científico publicado en 2004

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

artículo científico publicado en 2010

Development of pharmacodynamic biomarkers for ATR inhibitors.

artículo científico publicado en 2014

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

artículo científico publicado en 2001

Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cells.

artículo científico publicado en 1996

Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro.

artículo científico publicado en 1998

Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.

artículo científico publicado en 2000

Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro.

artículo científico publicado en 1999

Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials

artículo científico publicado en 2010

Effect of chronic N,N-diethylnitrosamine on the excision of O6-ethylguanine from rat liver DNA ⬇️

artículo científico publicado el 1 de noviembre de 1979

Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair.

artículo científico publicado en 2004

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

artículo científico publicado en 2015

Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors

artículo científico publicado en 2018

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer

artículo científico publicado en 2008

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types

artículo científico publicado en 2019

Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells

scientific article published on 04 April 2020

Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.

artículo científico publicado en 2011

High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers

artículo científico publicado en 2015

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

artículo científico publicado en 2011

Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?

artículo científico publicado en 2016

In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity.

artículo científico publicado en 2001

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue

artículo científico publicado en 2001

Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717

scientific article published on 01 June 1987

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase

artículo científico publicado en 2018

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

artículo científico publicado en 2009

Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717.

artículo científico publicado en 1986

Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.

artículo científico publicado en 2005

Modulation of dipyridamole action by α1acid glycoprotein

artículo científico publicado en 1989

Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.

artículo científico publicado en 2004

Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP)

artículo científico publicado en 1995

Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein.

artículo científico publicado en 2011

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib

scientific article published on 26 January 2015

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS.

artículo científico publicado en 2017

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.

scientific article published on 18 January 2011

PARP inhibitors for anticancer therapy

artículo científico

PARP inhibitors for cancer therapy.

artículo científico publicado en 2005

PARP inhibitors target ATM+p53-defective gastric cancer.

artículo científico publicado en 2014

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.

artículo científico publicado en 2015

PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer

artículo científico publicado en 2020

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

artículo científico publicado en 2016

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

artículo científico publicado en 2016

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

artículo científico publicado en 2008

Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors

artículo científico publicado en 2016

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma

artículo científico

Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers ⬇️

artículo científico publicado el 15 de junio de 2011

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

artículo científico publicado en 1998

Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors.

artículo científico publicado en 2004

Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.

artículo científico publicado en 2005

Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells

article

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

artículo científico publicado en 2000

Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.

artículo científico publicado en 1999

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells

artículo científico publicado en 2009

Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301.

artículo científico publicado en 2011

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

artículo científico publicado en 2007

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.

artículo científico publicado en 2014

Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines

artículo científico publicado en 1999

Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody

scientific article published on 01 January 1986

Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives

artículo científico publicado en 2002

Probing the active site and mechanism of action of O6-methylguanine-DNA methyltransferase with substrate analogues (O6-substituted guanines)

scientific article published on 01 October 1994

Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of [...]

artículo científico publicado en 2007

Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.

artículo científico publicado en 2003

Resistance-modifying agents. 11.(1) Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to alpha1-acid glycoprotein.

artículo científico publicado en 2004

Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)

artículo científico publicado en 1998

Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase

artículo científico publicado en 2000

Searching for Cyclin-Dependent Kinase Inhibitors Using a New Variant of the Cope Elimination

artículo científico publicado en 2006

Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage ⬇️

artículo científico publicado el 1 de enero de 1997

Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.

artículo científico publicado en 2017

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

artículo científico publicado en 2005

Strategies Employed for the Development of PARP Inhibitors.

artículo científico publicado en 2017

Strategies employed for the development of PARP inhibitors

artículo científico publicado en 2011

Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH).

artículo científico publicado en 2017

Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2

artículo científico publicado en 2007

Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2

artículo científico publicado en 2003

Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors.

artículo científico publicado en 2010

Targeting the ATR-CHK1 Axis in Cancer Therapy

artículo científico publicado en 2017

Targeting the DNA double strand break repair machinery in prostate cancer

artículo científico publicado en 2011

Targeting the S and G2 checkpoint to treat cancer.

artículo científico publicado en 2011

Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.

artículo científico publicado en 2005

The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation

artículo científico publicado en 2018

The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients.

artículo científico publicado en 2017

The impact of p53 status on cellular sensitivity to antifolate drugs.

artículo científico publicado en 2001

The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

artículo científico publicado en 2005

The quantitation by radioimmunoassay of 2′-deoxyuridine 5′-triphosphate in extracts of thymidylate synthase-inhibited cells

artículo científico publicado en 1989

The role of PARP in DNA repair and its therapeutic exploitation

artículo científico publicado en 2011

The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.

artículo científico publicado en 1995

The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis

artículo científico publicado en 2014

Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer.

artículo científico publicado en 2007

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

artículo científico publicado en 2010

Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.

artículo científico publicado en 2003

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules

artículo científico publicado en 2014

Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer

artículo científico publicado en 2014

Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer.

artículo científico publicado en 2016

Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?

artículo científico publicado en 2009

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.

artículo científico publicado en 2015

Visualization of a DNA-PK/PARP1 complex.

artículo científico publicado en 2012

Warburg and Krebs and related effects in cancer

scientific article published on 27 September 2019

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

artículo científico publicado en 2019

mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition

artículo científico publicado en 2015

Lista de obras de N J Curtin

1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.

4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

A radioimmunoassay for deoxythymidine triphosphate

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms

Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples.

Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines

Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

Changes in developmental-specific enzyme activities during experimental hepatocarcinogenesis in the rat in vivo [proceedings]

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor

Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K

Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition ⬇️

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

DNA damage checkpoint kinases in cancer

DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767.

DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype ⬇️

DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

Defective homologous recombination in human cancers.

Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

Development of pharmacodynamic biomarkers for ATR inhibitors.

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cells.

Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro.

Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.

Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro.

Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials

Effect of chronic N,N-diethylnitrosamine on the excision of O6-ethylguanine from rat liver DNA ⬇️

Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair.

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types

Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells

Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.

High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?

In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity.

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue

Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717.

Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.

Modulation of dipyridamole action by α1acid glycoprotein

Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.

Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP)

Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein.

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS.

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.

PARP inhibitors for anticancer therapy

PARP inhibitors for cancer therapy.

PARP inhibitors target ATM+p53-defective gastric cancer.

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.

PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma

Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers ⬇️

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors.

Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.

Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells

Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301.